One year of experience with L-Dopa in Parkinson's disease
Henry, P.; Lacut, J.Y.; Pouget-Abadie, J.; Bergouignan, M.; Leng-Lĕvy, J.
Bordeaux Medical 4(5): 1581-1591
1971
ISSN/ISBN: 0021-7867 PMID: 5569952 Document Number: 33969
Document emailed within 1 workday
Related Documents
Figuerido, J.A.; De la Herrán, J. 1970: Personal experience in the treatment of Parkinson's disease with L-Dopa Revista Clinica Espanola 119(6): 555-562Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Lees, A.J. 1986: L-dopa treatment and Parkinson's disease Quarterly Journal of Medicine 59(230): 535-547
Völler, G. 1970: L-dopa in the treatment of Parkinson's disease Die Medizinische Welt 27: 1267-1268
Dalle Ore, G.; Bricolo, A.; Robotti, E.; Bazzan, A.; Mazza, C. 1970: The treatment of Parkinson's disease with L-dopa Il Policlinico. Sezione Pratica 77(16): 509-524
Pendefunda, G.; Pollingher, B.; Stefanache, F.; Gavril, A.; Oprisan, C.; Merling, M.; Nemteanu, E.; Ciunru, M.; Koropitzer, I. 1975: The treatment with L-dopa and amantadine in Parkinson's disease Therapia Hungarica 23(1): 12-16
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Petit, H. 1984: Early or late dopa therapy in Parkinson's disease Presse Medicale 13(36): 2213
Muenter, M.D.; Sharpless, N.S.; Tyce, G.M. 1972: Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease Mayo Clinic Proceedings 47(6): 389-395
Angel, R.W.; Alston, W.; Garland, H. 1971: L-dopa and error correction time in Parkinson's disease Neurology 21(12): 1255-1260
Barbeau, A.; Gillo-Joffroy, L.; Mars, H.; Arsenault, A. 1972: Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602 Revue Canadienne de Biologie 31(Suppl): 169-174
Broussolle, E. 2000: Dopa-therapy in the treatment of early stage Parkinson's disease Revue Neurologique (Paris) 156(2 Part 2): 91-97
Sigwald, J.; Raymondeaud, C. 1970: Abnormal movements observed during treatment of Parkinson's disease with L-dopa Revue Neurologique (Paris) 122(2): 103-112
Selby, G. 1976: The influence of previous stereotactic thalamotomy on l-dopa therapy in Parkinson's disease Proceedings of the Australian Association of Neurologists 13: 55-60
Dzudza, M.; Dzudza, D. 1974: Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease Medicinski Arhiv 28(4): 407-415
Casacchia, M.; Barba, C.; Ruggieri, S.; Zamponi, A.; Agnoli, A. 1974: Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination Rivista di Neurologia 44(5): 303-330